Basket cover image
15 handpicked stocks

Global Trade Shift: China's New Export Routes

China's exports surged unexpectedly as companies rushed shipments to beat the expiration of a trade truce with the U.S. This shift is creating investment opportunities in the Southeast Asian and Belt and Road Initiative economies that are facilitating this redirected trade.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at août 7

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

YGMZ

MingZhu Logistics Holdings Ltd

YGMZ

Current price

$0.81

LSH

LAKESIDE HOLDING LTD.

LSH

Current price

$1.03

ATXG

ADDENTAX GROUP CORP

ATXG

Current price

$0.62

About This Group of Stocks

1

Our Expert Thinking

China's unexpected export surge, driven by companies rushing shipments before U.S. trade agreements expire, signals a major shift in global commerce. This redirection away from direct U.S. channels towards Southeast Asian and Belt and Road economies creates significant investment opportunities in the infrastructure facilitating this new trade flow.

2

What You Need to Know

This group focuses on companies operating in critical sectors like logistics, freight forwarding, port management, and e-commerce fulfilment. These businesses are positioned to handle increased trade volumes and benefit from new investments in supply chain infrastructure as global trade patterns evolve.

3

Why These Stocks

Each company was handpicked by professional analysts for their strategic position in capturing value from this supply chain realignment. They're the facilitators of rerouted trade, offering tactical exposure to structural changes in global commerce and potential growth tied to evolving geopolitical dynamics.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+42.44%

Group Performance Snapshot

42.44%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 42.44% over the next year.

13 of 14

Stocks Rated Buy by Analysts

13 of 14 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🌏

Trade Routes Are Shifting

China's 7.2% export surge whilst direct U.S. exports dropped 21.6% signals a massive redirection of global trade flows. Companies facilitating these new routes could see unprecedented demand.

📈

Infrastructure Investment Boom

Southeast Asian and Belt and Road economies are receiving increased investment to handle rerouted trade volumes. The logistics companies managing this transition stand to benefit significantly.

First-Mover Advantage

These handpicked companies are already positioned at the centre of this supply chain realignment. Getting in early could mean capturing value as this structural shift accelerates.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.